



## Cumulative Index to Volume 21

### Volume 21

February	VENTRICULAR ASSIST DEVICES AND THE ARTIFICIAL HEART, pages 1–146
May	INFECTIVE ENDOCARDITIS, pages 147–288
August	PREVENTION OF CARDIOVASCULAR DISEASE, pages 289–490
November	CARDIOVASCULAR COMPUTED TOMOGRAPHY, pages 491–673

*Note:* Page numbers of article titles are in **boldface** type.

### A

Abdominal left ventricular assist device (ALVAD), 3–4

Aberrant immune activation with LVAD implantation systemic consequences of, 129–132

Aberrant T-cell activation LVAD surface result in monocyte–T-cell interactions on, 129

AbioCor, 9, 121–124 described, 122 external components of, 122–123 historical background of, 121–122 indications for, 123 internal components of, 122 patient-carried electronics in, 123 studies of, 123–124

AbioCor TAH as destination therapy, 70

ABIOMED BVS 5000 VAD, 6, 38–40

Abscess(es) metastatic infective endocarditis and, 278 paravalvular infective endocarditis and, 274–275

Abuse drug as factor in surgical treatment for infective endocarditis, 248–249

Abuser(s) drug IV

infective endocarditis in, 167–176. *See also* Infective endocarditis, in IV drug abusers.

ACE inhibitors. *See* Angiotensin-converting enzyme (ACE) inhibitors.

#### Activity(ies)

in outpatient management of patients on long-term assist devices, 102

#### Acute cardiogenic shock

management of, 43–50. *See also* Cardiogenic shock, acute, management of.

#### Acute coronary syndromes thrombosis in, 303

#### Acute fulminant myocarditis short-term VADs for, 79

#### Acute peripheral vascular occlusion in infective endocarditis, 165–166

#### Adult Treatment Panel III (ATP III) report on cholesterol management, 393–398. *See also* National Cholesterol Education Program (NCEP), guidelines for cholesterol management, ATP III report on.

#### Age

as factor in extracorporeal mechanical circulatory support devices, 29 as factor in surgical treatment for infective endocarditis, 248 of heart as factor in coronary calcium use, 543–544

#### Alcohol

and health history of, 450 biology of, 452–453

**Alcohol (continued)**

- in vascular biology, 453-454
- moderate consumption of
  - in cardiovascular disease prevention, 449-457
  - reduction of
    - in hypertriglyceridemia management, 422-423

**ALVAD.** *See Abdominal left ventricular assist device (ALVAD).*

**Aneurysm(s)**

- aortic
  - MDCT of, 610-613

**Angiography**

- in coronary arteriosclerosis and coronary artery calcium, 523-524
- MDCT
  - of aorta, 610
- minimally invasive
  - using CT
  - clinical results of, 549-559. *See also Computed tomography (CT), minimally invasive angiography using.*

**peripheral arterial**

- MDCT with, 621-623

**pulmonary**

- for pulmonary embolism, 629-630

**Angiotensin-converting enzyme (ACE) inhibitors** in cardiovascular disease prevention, 474-475

**Antibiotic(s)**

- for coronary artery disease, 346-349
- for infective endocarditis in HIV-1-infected patients, 175
- for infective endocarditis in IV drug abusers, 171-174
- for prosthetic valve endocarditis, 259-260

**Anticoagulant(s)**

- for prosthetic valve endocarditis, 262
- in cardiovascular disease prevention, 476
- in CardioWest TAH implantation, 110-113

**Anticoagulation**

- mechanical circulatory support and, 32

**Antimicrobial agents.** *See Antibiotic(s).*

**Antiplatelet agents**

- in cardiovascular disease prevention, 476

**Aorta**

- MDCT angiography of, 610
- MDCT of, 605-627. *See also Multi-detector row computed tomography (MDCT).*

**Aortic aneurysm**

- MDCT of, 610-613

**Aortic dissection**

- MDCT of, 614-618

**Aortic trauma**

- MDCT of, 619-621

**Apoptosis**

- in heart failure, 88-89

**Arrhythmia(s)**

- extracorporeal mechanical circulatory support devices for, 31
- VAD response to, 24

**Arrow LionHeart pump**

- as destination therapy, 69

**Arteriosclerosis**

- coronary

- coronary calcium and, 521-528. *See also Coronary calcium, coronary arteriosclerosis and.*

**Arthralgia(s)**

- in infective endocarditis, 162

**Arthritis**

- in infective endocarditis, 162

**Artificial hearts.** *See also specific types, e.g., CardioWest.*

**AbioCor**

- patient selection for, 121-124

**CardioWest**

- patient selection for, 119-121

- infections of, 267

- patient selection for, 119-125

**Atherogenesis**

- diabetes and, 399-400

- inflammation in, 315-332

- clinical applications of, 317-319

- prevention of, 320-322

**Atherosclerosis**

- Chlamydia pneumoniae* and, 336-343

- animal studies of, 340-341

- historical background of, 336-337

- mechanistic studies of, 341-342

- pathologic evidence of, 338-340

- serologic evidence of, 337-338

- CMV and, 349-351

- C-reactive protein and, 328-329

- diagnosis of

- CT and MRI in, 642-650

- Helicobacter pylori* and, 343-344

herpes viruses and, 352  
 HIV and, 352-353  
 influenza virus and, 352-353  
*Mycoplasma pneumoniae* and, 344-345  
 pathogen burden as aggregate serologic risk factor for, 353  
 periodontal disease and, 346

Atherosclerotic plaque  
 coronary calcium and, 535-537

Atherosclerotic ulcer  
 penetrating  
 and intramural hematoma  
 MDCT of, 618-619

ATP III. *See Adult Treatment Panel III (ATP III).*

Axial blood flow pumps  
 advantages of, 10  
 hemodynamics characteristics of, 24-25

## B

Bacteremia  
 persistent  
 surgical treatment for infective endocarditis for, 246  
*Staphylococcus aureus*, 219-233. *See also Staphylococcus aureus bacteremia.*

Bacteria  
 extracellular fastidious  
 in infective endocarditis diagnosis, 211  
 isolation of  
 in infective endocarditis, 197-205  
*Bartonella* serology  
 in infective endocarditis diagnosis, 210  
*Bartonella* sp  
 in infective endocarditis diagnosis, 212

B-cell hyperreactivity  
 in LVAD recipients, 132-134  
 therapeutic interventions for, 134-137

Bile acid sequestrants  
 for lipid disorders, 369

Biomaterial(s)  
 implanted  
 human immunologic responses to, 127-129

Bleeding  
 mechanical circulatory support and, 32

B-Blocker therapy  
 in cardiovascular disease prevention, 475-476

Blood cultures  
 in infective endocarditis diagnosis, 199-203

Blood flow pumps  
 axial  
 advantages of, 10  
 Blood pressure  
 exercise training effects on, 441  
 Body weight  
 composition of, 440-441

## C

Calcium  
 coronary  
 coronary artery disease related to, 521-534

Calcium homeostasis  
 LVAD effects on, 90-91

Carbohydrate(s)  
 reduction of  
 in hypertriglyceridemia management, 422

Carbohydrate metabolism  
 exercise training effects on, 440

Cardiac rehabilitation  
 as secondary prevention, 444  
 compliance in, 442-444  
 cost effectiveness of, 444  
 effects on cardiovascular outcomes, 435-448  
 participation in, 442-444

Cardiac valvular disease  
*Staphylococcus aureus* bacteremia due to, 221

Cardiogenic shock  
 acute  
 management of, 43-50  
 devices in, 43-45  
 historical background of, 43-44  
 IABP, 43-44  
 VADs, 44-45  
 postcardiotomy  
 short-term VADs for, 78-79

Cardiomyopathy  
 quantitative CT methods in, 571

Cardiopulmonary bypass  
 historical perspective of, 1-2

Cardiovascular diseases  
 antihyperglycemic agents and, 401-402  
 cardiac rehabilitation effects on, 435-448  
*See also Cardiac rehabilitation.*  
 C-reactive protein and, 315-325  
 C-reactive protein as predictor of, 327-331  
 epidemiology of, 450-452

Cardiovascular diseases (*continued*)

- exercise effects on, 435-448. *See also*
  - Exercise training.*
- hyperglycemia and, 401
- in diabetes, 399-413. *See also* *Diabetes.*
- inflammation and, 315-325
- obesity and, 424-425
- prevention of
  - in daily practice, 471-482
  - ACE inhibitors, 474-475
  - anticoagulants, 476
  - antiplatelet agents, 476
  - B-blocker therapy, 475-476
  - cigarette smoking cessation, 471-472
  - hormone replacement therapy, 476-477
  - hyperlipidemia management, 472-473
  - hypertension management, 473-474
  - physical activity, 475
  - weight reduction, 475
- lack of implementation in, 477-478
- moderate alcohol and wine
  - consumption in, 449-457. *See also*
    - Alcohol; Wine.*
- primary and secondary
  - evidence supporting, 471-477
- programs for
  - strategies in development of, 478-479

## CardioWest TAH, 8, 119-121

- described, 120
- historical background of, 106-107, 119
- implantation of, 110
  - anticoagulation therapy and
    - monitoring during, 110-113
  - guidelines for, 110
  - survival following, 113-115
  - techniques for, 110
  - indications for, 110
- indications for, 120-121
- studies of, 121
- ventricles and console of, 107-109

## Cellular restoration, 91-92

Centrifugal pumps

- hemodynamics characteristics of, 25

Cerebral vascular accident

- in infective endocarditis, 164-165

Chest radiography

- for pulmonary embolism, 629
- in infective endocarditis diagnosis, 192

CHF. *See* *Congestive heart failure (CHF).*

*Chlamydia pneumoniae*

- atherosclerosis due to, 336-343. *See also*
  - Atherosclerosis, Chlamydia pneumoniae and.*

## Cholesterol

- isolated low HDL
  - management of, 382-383
- LDL, 363-375. *See also* *Low-density lipoprotein cholesterol (LDL-C).*
- national education treatment for. *See National Cholesterol Education Program Adult Treatment Panel (NCEP-ATP).*
- guidelines of, 363-365
- NCEP guidelines for
  - ATP III report on, 393-398. *See also*
    - National Cholesterol Education Program (NCEP), guidelines for cholesterol management, ATP III report on.*

## Cholesterol absorption inhibitors

- for lipid disorders, 370-371

Chronic wasting disease

- in infective endocarditis, 162

## Cigarette smoking

- cessation of
  - in cardiovascular disease prevention, 471-472

## Circulatory failure

- right-sided
  - mechanical circulatory support and, 32
  - VADs for, 53-54

## Circulatory support

- mechanical
  - early history of, 1-2

CMV. *See* *Cytomegalovirus (CMV).*

## Community preparation

- in outpatient management of patients on long-term assist devices, 101

## Competency

- in outpatient management of patients on long-term assist devices, 99

## Compliance

- in cardiac rehabilitation, 442-444

## Computed tomography (CT)

- cardiac, 491-513, 561-585
  - advantages of, 505-506
  - complementary results of, 637-653
  - evolution of, 492-505
  - first-phase of, 493-500
  - fourth phase of, 501-505

future possibilities for, 506-508  
 limitations of, 505-506  
 of coronary calcification in ischemic heart disease, 565  
 of ischemic left ventricular myocardium, 565-570  
 of myocardial infarction, 565-570  
 quantitative methods, 570-582  
 second phase of, 500-501  
 third phase of, 501

coronary calcium scanning with  
 clinical use of, **535-547**. *See also Coronary calcium scanning, with CT*.

described, 491  
 diagnosis of, 192-193  
 fast  
 in myocardial vasculature imaging, **587-604**. *See also Myocardial vasculature, CT in imaging of, fast*.  
 for deep venous thrombosis, 631-634  
 for pulmonary embolism, 631-634  
 historical background of, 491  
 image reconstruction in, 515-518  
 definitions associated with, 515  
 historical background of, 515  
 technique of, 515-518  
 in atherosclerosis, 642-650  
 in venous thromboembolic disease, **629-636**.  
*See also Venous thromboembolic disease, CT in.*

minimally invasive angiography using  
 clinical applications of  
 results of, 553-555  
 clinical results of, **549-559**  
 methods in, 550-551  
 results of, 551-553  
 visualization of non-calcified plaque on, 555-556

of coronary arteries  
 complementary results of, **637-653**  
 physics and dosimetry in, **515-520**  
 quantitative methods  
 in cardiac assessment, 570-582. *See also specific disorder, e.g., Cardiomyopathy.*  
 radiation dose for, 518-519  
 three-dimensional microscopic  
 in myocardial vasculature imaging, **587-604**. *See also Myocardial vasculature, CT in imaging of, three-dimensional microscopic.*

Congestive heart failure (CHF)  
 described, 87

infective endocarditis and, 273-274  
 surgical treatment for, 237-242  
 mortality of, 1  
 prevalence of, 1, 57

Continuous blood flow  
 technology in  
 advances in, 9-10

Contrast venography  
 for deep venous thrombosis, 630

Coronary arteriosclerosis  
 coronary artery calcium and, 521-528. *See also Coronary artery calcium, coronary arteriosclerosis and.*

Coronary artery disease. *See also Atherosclerosis.*  
 chronic infection and, **333-362**  
 chronic inflammation as predictor of, 333-336  
 coronary calcium related to, **521-534**. *See also Coronary calcium, coronary artery disease related to.*  
 diagnosis of  
 CT and MRI in, 638-642  
 extracorporeal mechanical circulatory support devices for, 31  
 pathogen burden as aggregate serologic risk factor for, 353  
 treatment of  
 antimicrobial agents in, 346-349  
 VAD response to, 24

Coronary artery stenosis  
 epicardial  
 microvascular dysfunction in presence of, 591-592

Coronary calcification  
 in ischemic heart disease  
 detection of  
 CT in, 565

Coronary calcium  
 atherosclerotic plaque and, 535-537  
 coronary arteriosclerosis and, 521-522  
 coronary angiography in, 523-524  
 exercise ECG in, 527  
 extent of disease, 522-527  
 histopathology of, 523  
 intracoronary ultrasonography in, 524-527  
 myocardial perfusion measurements in, 527  
 natural history of, 527-528  
 severity factors, 522-527  
 coronary artery disease related to, **521-534**  
 heart age and

**Coronary calcium (continued)**  
  factors related to, 543-544  
  high-risk coronary plaques and, 528-529  
  long-term risk as factor in use of, 543-544  
  progression of, 529-530  
  with CT  
    clinical outcomes of, 539-541  
    in asymptomatic patients, 541-542

**Coronary calcium scanning**  
  with CT  
    clinical use of, 535-547  
    electron beam tomography methods in, 536-537  
    multi-detector methods in, 537-538  
      vs. electron beam tomography, 538  
    radiation exposure in, 539

**Coronary heart disease**  
  mortality due to, 459  
  prevention of  
    barriers to, 459-470  
    cardiologist-related, 464-467  
    patient-related, 460-461  
    physician intervention-related, 461-464  
  risk factors for, 364

**Coronary plaque**  
  high-risk  
    coronary artery calcium and, 528-529

**Coxiella burnetii** morphology  
  in infective endocarditis diagnosis, 207

**Coxiella burnetii** serology  
  in infective endocarditis diagnosis, 209

**C-reactive protein**  
  as predictor of cardiovascular disease, 327-331  
  atherosclerosis due to, 328-329  
  cardiovascular disease and, 315-325  
  lowering of  
    methods for, 330  
  measurements of  
    guidelines for, 329-330  
  plaque instability due to, 328-329

**CT.** *See Computed tomography (CT).*

**Cyclophosphamide**  
  for B-cell hyperreactivity, 134-137

**Cytomegalovirus (CMV)**  
  atherosclerosis and, 349-351

**D**

**D-dimer tests**  
  for deep venous thrombosis, 630  
  for pulmonary embolism, 630

**Deep venous thrombosis**  
  diagnostic tests for, 630-633  
    contrast venography, 630  
    CT, 631-634  
    D-dimer tests, 630  
    MRI, 630  
    venous ultrasonography, 630

**Destination therapy**  
  devices as, 67-73

**Device(s)**  
  as destination therapy, 67-73.  
    *See also* specific device, e.g., *Pulsatile LVADs*.  
  clinical trials of, 71-72  
  patient selection in, 70-71

**Diabetes**  
  atherogenesis and, 399-400  
  cardiovascular disease in patients with, 399-413  
  hypertension in patients with, 406-407  
  LDL-C in  
    statin trials for, 403-404  
    with hypertriglyceridemia, 404-406  
  lipid disorders in patients with, 403-406  
  prevention of  
    studies of, 403  
  procoagulant state in, 408-409  
  renal disease in patients with, 408

**Diet(s)**  
  vascular outcomes of, 416-419

**Dietary fiber**  
  in obesity management, 421

**Dietary modification**  
  in obesity management, 415-433. *See also* *Obesity, treatment of, dietary modification in.*

**Displacement pumps**  
  hemodynamics characteristics of, 25

**Distal microembolism**  
  microvascular dysfunction in response to, 592-594

**Dosimetry**  
  in CT, 515-520

**Drug(s)**  
  in outpatient management of patients on long-term assist devices, 99

**Drug abuse**  
  as factor in surgical treatment for infective endocarditis, 248-249

Drug abusers

IV

  infective endocarditis in, 167-176. *See also* *Infective endocarditis*, in IV drug abusers.

**E**

EBCT. *See* *Electron beam computed tomography (EBCT)*.

ECG. *See* *Electrocardiography (ECG)*.

Echocardiography

  abnormal findings on

    in infective endocarditis, 163-164

  in infective endocarditis diagnosis, 185-192

    cost effectiveness of, 191-192

    described, 185-186

    findings of, 188-191

    technique of, 186-187

  in *Staphylococcus aureus* bacteraemia diagnosis, 223-225

  transesophageal

    for pulmonary embolism, 630

ECMO. *See* *Extracorporeal membrane oxygenation (ECMO)*.

Electrical synchrony

  importance of, 145-146

Electrocardiography (ECG)

  exercise

    in coronary arteriosclerosis and coronary artery calcium, 527

Electron beam computed tomography (EBCT), 549-556

  in coronary calcium scanning, 536-537

    vs. multi-detector CT methods, 538

  minimally invasive angiography using

    clinical applications of

    results of, 553-555

    methods in, 550

    results of, 551

Electron microscopy

  in infective endocarditis diagnosis, 208-209

Embolism

  pulmonary. *See* *Pulmonary embolism*.

Embolus(i)

  pulmonary

    septic

    in infective endocarditis, 164

Emergency issues

  in outpatient management of patients on long-term assist devices, 100

Endocarditis

  fungal

    surgical treatment for, 246-247

  infective

    global understanding of, 147-158. *See also* *Infective endocarditis*, global understanding of.

  left-sided native valve

    treatment of, 227

  prosthetic valve, 163. *See* *Prosthetic valve endocarditis*.

    surgical treatment of, 247

  right-sided native valve endocarditis

    treatment of, 227

*Staphylococcus aureus*, 219-233. *See also* *Staphylococcus aureus endocarditis*.

Endothelial dysfunction

  uncoupling of nitric oxide synthases and, 294-295

Endothelial function

  exercise training effects on, 441

  myocardial perfusion measurement in, 590-591

Endothelial nitric oxide synthase (eNOS)

  endogenous antagonists of, 297

  expression of, 295-297

Endothelium

  in vascular tone modulation, 289-290

End-stage heart failure

  future directions in, 143-147

eNOS. *See* *Endothelial nitric oxide synthase (eNOS)*.

Epicardial coronary artery stenosis

  microvascular dysfunction in presence of, 591-592

Exercise. *See* *Exercise training*.

Exercise ECG

  in coronary arteriosclerosis and coronary artery calcium, 527

Exercise tolerance

  exercise training and, 438-439

Exercise training

  blood pressure effects of, 441

  body weight and composition effects of, 440-441

  carbohydrate metabolism effects of, 440

  cardiovascular morbidity effects of, 437-438

  cardiovascular mortality effects of, 436-437

Exercise training (*continued*)  
  clinical outcomes of  
    intermediate, 439-440  
    primary, 436-439  
  effects on cardiovascular outcomes, 435-448  
  endothelial function effects of, 441  
  exercise tolerance due to, 438-439  
  physical functioning effects of, 442  
  plasma lipid values and, 439-440  
  quality-of-life outcomes related to, 441-442  
  strength due to, 439

Extracardiac invasive infections  
  surgical treatment for infective endocarditis and, 248

Extracellular fastidious bacteria  
  in infective endocarditis diagnosis, 211

Extracellular matrix alterations  
  heart failure progression caused by, 89

Extracorporeal centrifugal pumps, 35

Extracorporeal mechanical circulatory support devices, 29-42. *See also Mechanical circulatory support (MCS)*.

Abiomed BVS 5000, 38-40

adverse events associated with, 32

age as factor in, 29

ECMO, 33-35

extracorporeal centrifugal pumps, 35

for arrhythmias, 31

for coronary artery disease, 31

for valvular heart disease, 30-31

intracardiac shunts, 31

patient selection for, 29

Tandem Heart pVAD, 35-36

temporary

  considerations related to, 30-33

Thoratec Ventricular Assist System, 36-38

timing of, 29-30

types of, 33-40

Extracorporeal membrane oxygenation (ECMO), 33-35

## F

Fiber

  dietary

  in obesity management, 421

Fibrate(s)

  for diabetic dyslipidemia, 405-406

  for lipid disorders, 368-369

Fish oil

  in hypertriglyceridemia management, 423

Fluid dynamic-rotary pumps  
  hemodynamic characteristics of, 24

Fungal endocarditis  
  surgical treatment for, 246-247

Fungus(i)  
  isolation of  
    in infective endocarditis, 197-205

## H

HDL-C. *See High-density lipoprotein cholesterol (HDL-C)*.

Heart

  age of

    as factor in coronary calcium use, 543-544

  anatomy of, 561-565

  artificial. *See Artificial hearts*.

    infections of, 267

  assessment of

    CT in, 561-585. *See also Computed tomography (CT), cardiac*.

  CT of

    complementary results of, 637-653

  defects of

    congenital

    VAD response to, 24

  diseased

    near normal functional status of

    reasons for, 145

    recovering function by

    incapability of, 143-144

  infective endocarditis effects on, 148-149

  MRI of

    complementary results of, 637-653

  total artificial

    historical perspective of, 1-13. *See also*

*Total artificial hearts (TAHs)*.

Heart disease

  valvular

    extracorporeal mechanical circulatory support devices for, 30-31

Heart failure

  apoptosis in

    heart failure progression caused by, 88-89

  congestive. *See Congestive heart failure (CHF)*.

  end-stage

    future directions in, 143-147

    mortality resulting from

    reasons for, 146

    physiology of, 17-18

    progression of

left ventricular remodeling and, 87-89  
 apoptosis in heart failure and, 88-89  
 cardiac myocyte loss and, 88  
 cellular component alterations and, 88  
 extracellular matrix alterations and, 89  
 subcellular component alterations and, 88

reverse modeling in  
 feasibility of, 90-92

types of  
 assist devices for, 144-145

unexplained  
 in infective endocarditis, 162

**HeartMate**, 5-6, 57-58  
 as destination therapy, 68 *Helicobacter pylori*  
 atherosclerosis due to, 343-344

**Hematoma(s)**  
 atherosclerotic  
 penetrating  
 and intramural hematoma  
 MDCT of, 618-619

intramural  
 MDCT of, 618-619

**Herpes viruses**  
 atherosclerosis and, 352

**High-density lipoprotein cholesterol (HDL-C)**  
 isolated low  
 management of, 382-383

**HIV. See Human immunodeficiency virus (HIV).**

**Home documentation**  
 in outpatient management of patients on  
 long-term assist devices, 101

**Home evaluation**  
 in outpatient management of patients on  
 long-term assist devices, 101

**Hormone replacement therapy (HRT)**  
 in cardiovascular disease prevention, 476-477

**Human immunodeficiency virus (HIV)**  
 atherosclerosis and, 352

**Human immunodeficiency virus (HIV)-type 1-infected patients**  
 infective endocarditis in, **176-179**. *See also*  
*Infective endocarditis, in HIV-1-infected patients.*

**Hyperglycemia**, 401-403  
 cardiovascular events due to, 401  
 postprandial, 403

**Hyperlipidemia**  
 after solid organ transplantation  
 management of, 386-387  
 renal diseases-related  
 management of, 384-386  
 treatment of  
 in cardiovascular disease prevention, 472-473

**Hypertension**  
 in diabetics, 406-407  
 treatment of  
 in cardiovascular disease prevention, 473-474

**Hypertriglyceridemia**  
 and LDL-C  
 in diabetics, 404-406  
 differential diagnosis of, 378-381  
 treatment of, **377-382**  
 alcohol reduction in, 422-423  
 dietary carbohydrates limits in, 422  
 drugs in, 381-382  
 fish oil in, 423  
 nonpharmacologic approaches in, 381  
 weight loss in, 422-423  
 triglyceride metabolism in, 377-378

---

**I**

**IABP. See Intra-arterial-balloon-pump (IABP).**

**Image reconstruction**  
 in CT, 515-518

**Immunohistologic testing**  
 in infective endocarditis diagnosis, 208

**Implantable ventricular assist device (IVAD)**  
 Thoratec, 58

**Infarction(s)**  
 myocardial  
 short-term VADs for, 79

**Infection(s)**  
 chronic  
 coronary artery disease due to, **333-362**  
 in outpatient management of patients on  
 long-term assist devices, 99  
 mechanical circulatory support and, 32-33  
 of intracardiac devices, **253-271**. *See also*  
*specific infection and Intracardiac devices, infections of.*  
 uncontrolled  
 infective endocarditis and, 277-278

**Infectious endocarditis**

in *Staphylococcus aureus* bacteremia  
identification of, 223  
*Staphylococcus aureus*, 222-223

**Infective endocarditis**

acute peripheral vascular occlusion in, 165-166  
arthralgias in, 162  
arthritis in, 162  
cardiac risk factors associated with, 148-149  
cerebral vascular accident in, 164-165  
chronic wasting disease in, 162  
clinical presentation of, 159-166  
clinical response to patients with evaluation of, 279  
complications of, 273-282  
congestive heart failure, 273-274  
metastatic abscesses, 278  
paravalvular abscesses, 274-275  
renal, 279  
stroke, 275-277  
uncontrolled infection, 277-278  
current understanding of, 148  
dental effects of, 149  
diagnosis of, 150-151, 197-205  
bacteria isolation in, 197-205  
best practices in, 199-202  
chest radiography in, 192  
CT in, 192-193  
difficult-to-culture pathogens in identification of, 207-217  
*Bartonella* sp. in, 212  
*Bartonella* sp. serology in, 210  
*Coxiella burnetii* serology in, 209  
culture methods in, 210-213  
extracellular fastidious bacteria in, 211  
morphologic methods in, 207-209  
PCR amplification in, 213  
Q fever in, 211-212  
serologic testing in, 209-210  
Warthin-Starry technique in, 208  
echocardiography in, 185-192. *See also Echocardiography, in infective endocarditis diagnosis.*  
fungi isolation in, 197-205  
imaging techniques in, 185-195  
microbiologic findings in, 198-199  
MRI in, 192-193  
nuclear medicine imaging in, 193  
optimal antiseptic skin preparation in, 199  
optimal choice of blood culture media in, 201-202

optimal length of incubation for blood cultures in, 202

optimal number of blood cultures in, 200-201

optimal timing of blood cultures in, 199-200

optimal volume of blood for culture in, 201  
special considerations in, 203

echocardiogram in  
abnormal, 163-164

epidemiology of, 148

fever in, 159-161

future directions in, 151-154

global understanding of, 147-158

controlled clinical trials in, 154-156  
limitations in, 151

heart failure in, 162

host factors associated with, 148-150

in HIV-1-infected patients

causes of, 176

clinical characteristics of, 176

incidence of, 175-176

not related to IV drug abuse, 176-178  
causes of, 176-177

clinical characteristics of, 176-177

incidence of, 176

prognosis of, 178

treatment of, 178

prognosis of, 176

treatment of

antibiotic, 176

surgical, 176

in IV drug abusers, 167-176

causes of, 168

described, 167

diagnosis of, 169-171

prognosis of, 171

treatment of

antibiotic, 171-174

surgical, 174-175

valve involvement in, 168-169

intensive medical care and, 149-150

microorganisms and, 150

pathophysiology of, 197-198

periannular extension of infection in

treatment of

surgical, 242-245

pericarditis in, 162-163

prognosis of, 166

prosthetic valve endocarditis in, 163

recurrent, 279-280

regional variation in, 148

renal failure in, 165

sepsis in, 161-162  
 septic pulmonary emboli in, 164  
 signs and symptoms of, 159-166  
 study of  
     controlled clinical trials in, 154-156  
 treatment of, 151  
     complications of, 280-281  
     surgical  
         age as factor in, 248  
         drug abuse and, 248-249  
         extracardiac invasive infections due to, 248  
         indications for, 235-251  
         congestive heart failure, 237-242  
         difficult-to-treat organisms, 247  
         fungal endocarditis, 246-247  
         persistent bacteremia, 246  
         prosthetic valve endocarditis, 247  
         systemic embolization risk, 245-246  
         unstable prosthesis, 247  
         valve obstruction, 246  
         vegetations, 245-246  
     neurologic complications due to, 248  
     timing of, 236

**Inflammation**  
 and vascular remodeling, 454-455  
 cardiovascular disease and, 315-325  
 chronic  
     as coronary artery disease predictor, 333-336  
     causes of, 336  
     in atherogenesis, 315-332. *See also*  
         Atherogenesis, inflammation in.

**Influenza virus**  
 atherosclerosis and, 352-353

**Insulin**  
 for hyperglycemia  
 cardiovascular effects of, 402

**Insulin resistance**  
 metabolic syndrome and, 400-401

**Intermediate facility**  
 in outpatient management of patients on long-term assist devices, 98

**International Collaboration on Endocarditis Investigation, 147-158. *See also* Infective endocarditis, global understanding of.**  
 characteristics of, 153  
 cohort study, 153-154  
 database merger in, 152-153  
 working group in, 151-152

**Intra-aortic-balloon-pump (IABP)**  
 for acute cardiogenic shock, 43-44

**Intracardiac devices**  
 artificial hearts  
     infections of, 267  
 implantable electrophysiologic  
     infections of, 262-267  
         anatomy of, 262-263  
         classification of, 262-264  
         clinical presentation of, 265-266  
         epidemiology of, 264  
         management of, 266-267  
         microbiology of, 264-265  
         pathogenesis of, 262-264  
         risk factors for, 264  
     infections of, 253-271  
 left ventricular assist devices  
     infections of, 267

**Intracardiac masses**  
 quantitative CT methods in, 574-575

**Intracardiac shunts, 31**

**Intramural hematoma**  
 MDCT of, 618-619

**Intravenous drug abusers**  
 infective endocarditis in, 167-176. *See also*  
     Infective endocarditis, in IV drug abusers.

**Ischemic heart disease**  
 coronary calcification in  
     detection of  
     CT in, 565

**Ischemic left ventricular myocardium**  
 assessment of  
     CT in, 565-570

**Isolated low HDL-C**  
 management of, 382-383

**IVAD. *See* Implantable ventricular assist device (IVAD).**

---

**J**

Jarvik 2000  
     as destination therapy, 69-70

Jarvik-7, 8, 9

---

**K**

Kidney(s)  
 infective endocarditis effects on, 165, 279

**L**

**LDL-C.** *See Low-density lipoprotein cholesterol (LDL-C).*

**Left ventricular assist devices (LVADs),** 2-5

effect on calcium homeostasis, 90-91  
effect on mechanical function of heart, 90  
effect on neurohormone levels, 91  
implantation of

aberrant immune activation with  
systemic consequences of, 129-132

long-term

historical background of, 51-52  
indications for, 51-56

pulsatile

as destination therapy, 67-69

pulsatile implantable, 57-65. *See also Pulsatile LVADs, implantable.*

recipients of

B-cell hyperreactivity in, 132-134

T-cell defects in

clinical consequences of, 132-134

**Left ventricular myocardium**

ischemic

assessment of

CT in, 565-570

**Left-sided native valve endocarditis**

treatment of, 227

**Lifestyle change**

therapeutic

in obesity management, 416

**LionHeart LVAD,** 58-60

**Lipid disorders**

in diabetics, 403-406

treatment of, 368-371.

*See also* specific disorder, e.g.,

*Hypertriglyceridemia.*

bile acid sequestrants in, 369

combination drug therapy in, 370

fibrates in, 368-369

hypertriglyceridemia, 377-382

nicotinic acid in, 369

selective cholesterol absorption inhibitors

in, 370-371

statins in, 368

**Lipoprotein(a)**

elevated

management of, 383-384

**Long-term assist devices**

outpatient management of, 97-103

activities in, 102

assessment of need for intermediate facility

in, 98

community preparation in, 101

competency in, 99

complications in, 102-103

discharge preparation, 98-100

drugs in, 99

emergency issues in, 100

equipment in, 100

follow-up care, 102

home documentation in, 101

home evaluation in, 101

infection and, 99

nutrition in, 98

practitioner's role in, 97-98

reconditioning in, 98

support persons in, 99-100

transportation issues in, 100

travel issues in, 100

work issues in, 101-102

wound management in, 99

**Low-density lipoprotein cholesterol (LDL-C)**

goals for, 363-375

target levels, 366-368

hypertriglyceridemia and

in diabetics, 404-406

in diabetics

statin trials for, 403-404

treatment for

method of, 367-368

**LVADs.** *See Left ventricular assist devices (LVADs).*

**LVAS.** *See Novacor left ventricular assist system (LVAS).*

**M**

**Magnetic resonance imaging (MRI)**

in atherosclerosis, 642-650

in deep venous thrombosis, 630

in infective endocarditis diagnosis, 192-193

of heart and coronary arteries

complementary results of, 637-653

of pulmonary embolism, 630

**MCS.** *See Mechanical circulatory support (MCS).*

**MDCT.** *See Multi-detector row computed tomography (MDCT).*

**Mechanical circulatory support (MCS),** 29-42.

*See also* *Extracorporeal mechanical circulatory support devices.*

adverse events associated with, 32

- anticoagulation due to, 32
- bleeding due to, 32
- device selection in, 30
- early history of, 1-2
- infection due to, 32-33
- right-sided circulatory failure due to, 32
- thromboembolism due to, 32
- weaning patients from
  - considerations in, 33
- Metabolic syndrome**
  - dietary modification in improving, 421-422
  - insulin resistance and, 400-401
  - obesity and, 401
- Metastatic abscess**
  - infective endocarditis and, 278
- Metformin**
  - for hyperglycemia
  - cardiovascular effects of, 401-402
- Methicillin**
  - resistance to
    - Staphylococcus aureus* bacteremia effects of, 222
- Microembolism**
  - distal
    - microvascular dysfunction in response to, 592-594
- Micro-Med-DeBakey VAD, 69**
- Microorganism(s)**
  - infective endocarditis due to, 150
- Microvascular dysfunction**
  - coronary
    - in response to distal microembolism, 592-594
  - in presence of epicardial coronary artery stenosis, 591-592
- Microvascular function**
  - changes during vessel growth, 590
- Molecular restoration, 91-92**
- Monocyte-T-cell interactions**
  - on LVAD surface result in aberrant T-cell activation, 129
- MRI. *See Magnetic resonance imaging (MRI).***
- Multi-detector row computed tomography (MDCT)**
  - in coronary calcium scanning, 537-538
  - vs. electron beam tomography, 538
  - of aorta, **605-627**
  - techniques in, 605-607
- of aortic aneurysm, 610-613
- of aortic dissection, 614-618
- of aortic trauma, 619-621
- of penetrating atherosclerotic ulcer and intramural hematoma, 618-619
- of peripheral arteries, **605-627**
  - techniques in, 605-607
- peripheral arterial angiography and, 621-623
- Multi-detector row computed tomography (MDCT) angiography**
  - of aorta, 610
- Multi-detector row computed tomography (MDCT) angiography post-processing, 607-610**
- Multi-detector spiral computed tomography, 549-556**
  - minimally invasive angiography using
    - clinical applications of
    - results of, 553-555
    - methods in, 550-551
    - results of, 551-553
- Mycoplasma pneumoniae***
  - atherosclerosis due to, 344-345
- Myocardial blood flow**
  - relationship to blood volume, 589-590
- Myocardial blood volume**
  - relationship to blood flow, 589-590
- Myocardial dysfunction**
  - alteration in contractile function
    - molecular basis of, 89-90
    - pathogenesis of, 87-95
- Myocardial infarction**
  - assessment of
    - CT in, 565-570
    - short-term VADs for, 79
- Myocardial perfusion measurements**
  - applications of, 590-594
  - in coronary arteriosclerosis and coronary artery calcium, 527
- Myocardial recovery**
  - after long-term VAD use, 79-84. *See also Ventricular assist devices (VADs), long-term.*
- VADs in, 75-85. *See also Ventricular assist devices (VADs).***
  - rationale for, 75-76
  - short-term, 76-79

**Myocardial vasculature**  
CT in imaging of  
fast, **587-604**  
future directions in, 601-602  
three-dimensional microscopic, **587-604**  
cryogenic, 599-601  
function of  
modeling indices of  
indicator dilution principles in, 588-589

**Myocarditis**  
acute fulminant  
short-term VADs for, 79

**Myocardium**  
ischemic left ventricular myocardium  
assessment of  
CT in, 565-570

**Myocyte(s)**  
cardiac  
loss of  
heart failure progression caused by, 88

**N**

National Cholesterol Education Program (NCEP)  
guidelines for cholesterol management  
ATP III report on, **393-398**  
described, 393-394  
new features of, 394-397  
9 steps in, 397-398

National Cholesterol Education Program Adult  
Treatment Panel (NCEP-ATP)  
LDL-C goals of, 363-364  
therapeutic lifestyle change diet of,  
364-365

National Health and Nutrition Examination  
Survey III (NHANES III), 364-365

**NCEP.** *See National Cholesterol Education  
Program (NCEP).*

Nephrotic syndrome  
management of, 384-385

Neurohormone levels  
LVAD effects on, 91

Neurologic complications  
surgical treatment for infective endocarditis  
and, 248

Niacin  
for diabetic dyslipidemia, 406

Nicotinic acid  
for lipid disorders, 369

Nitric acid production  
endothelial control of, **298-302**

Nitric oxide  
bioavailability in vascular diseases, 292-293  
in vascular tone regulation, 290-291  
production of  
alteration of, 292-293  
roles of, 290-291  
vasodilation by  
method of, 291

Nitric oxide synthases  
endothelial  
endogenous antagonists of, 297  
expression of, 295-297  
uncoupling of  
endothelial dysfunction due to, 294-295

Novacor, 57-58

Novacor left ventricular assist system (LVAS),  
4-6

Novacor pump  
as destination therapy, 68-69

Nuclear medicine imaging  
in infective endocarditis diagnosis, 193

Nutrition  
in outpatient management of patients on  
long-term assist devices, 98

**O**

Obesity  
assessment of patient with, 424  
cardiovascular disease and, 424-425  
defined, 424, 440  
metabolic syndrome and, 401  
pathophysiology of, 425-426  
treatment of  
dietary modification in, **415-433**  
dietary fiber, 421  
effects on lipids, 419-422  
in improving metabolic syndrome,  
421-422  
plant sterols, 419  
risk factor effects of, 419-422  
Step I and II diets, 415-416  
therapeutic lifestyle change, 416  
trans fatty acids, 419-421  
triglycerides levels, 422  
vascular outcomes of, 416-419  
goals in, 427-429  
modalities in, 427-429  
weight loss in, 422-423

**P**

Paravalvular abscess  
  infective endocarditis and, 274–275

PCR. *See Polymerase chain reaction (PCR).*

Penetrating atherosclerotic ulcer  
  and intramural hematoma  
    MDCT of, 618–619

Pericardial disease  
  quantitative CT methods in, 579–582

Pericarditis  
  in infective endocarditis, 162–163

Periodontal disease  
  atherosclerosis and, 346

Peripheral arterial angiography  
  MDCT with, 621–623

Peripheral arteries  
  MDCT of, 605–627. *See also Multi-detector row computed tomography (MDCT), of peripheral arteries.*

Physical activity  
  in cardiovascular disease prevention, 475

Physical functioning  
  exercise training effects on, 442

Physics  
  in CT, 515–520

Plant sterols  
  in obesity management, 419

Plaque  
  atherosclerotic  
    coronary calcium and, 535–537  
  coronary  
    high-risk  
      coronary artery calcium and, 528–529  
  non-calcified  
    visualization of  
      on minimally invasive angiography using CT, 555–556

Plaque instability  
  C-reactive protein and, 328–329

Plaque rupture  
  altered extracellular matrix breakdown and synthesis in, 305–307  
  determinants of, 303–304  
  in animal models, 307–209  
    thrombosis after, 307–308  
    triggers for, 307  
  mechanism of, 305–307

pathophysiology of, 303–314  
  plaque composition and, 304–305  
  role of, 303  
  stenosis severity and, 303–304

Plaque stabilization, 303–314  
  in animal models, 309

Plasma lipid values  
  exercise training effects on, 439–440

Plasmapheresis  
  for B-cell hyperreactivity, 134–135

Polymerase chain reaction (PCR) amplification  
  in infective endocarditis diagnosis, 213

Postcardiotomy shock, 45–46  
  postcardiogenic  
    short-term VADs for, 78–79

Precardiotomy shock, 46–48

Prosthesis(es)  
  unstable  
    surgical treatment for infective endocarditis for, 247

Prosthetic implants  
  *Staphylococcus aureus* bacteremia due to, 221

Prosthetic valve endocarditis, 253–262  
  clinical manifestations of, 257  
  diagnosis of, 257–259  
  in infective endocarditis, 163  
  laboratory manifestations of, 257  
  microbiology of, 255–256  
  pathogenesis of, 253–255  
  pathology of, 256  
  prevalence of, 253  
  risk factors for, 253  
  treatment of, 227–228  
    anticoagulants in, 262  
    antimicrobial, 259–260  
    surgical, 247, 260–262

Protein  
  C-reactive  
    cardiovascular disease and, 315–325.  
      *See also C-reactive protein.*

Pulmonary angiography  
  for pulmonary embolism, 629–630

Pulmonary emboli  
  septic  
    in infective endocarditis, 164

Pulmonary embolism  
  diagnostic algorithm for, 634–635

**Pulmonary embolism (continued)**

- diagnostic tests for, 629-630
  - chest radiography, 629
  - CT, 631-634
  - D-dimer tests, 630
  - MRI, 630
  - pulmonary angiography, 629-630
  - transesophageal echocardiography, 630
  - ventilation/perfusion lung scintigraphy, 629

**Pulsatile LVADs**

- as destination therapy, 67-69
- development of, 2-6
- implantable, **57-65**
  - complications of, 62-64
  - family training for, 61
  - follow-up protocol, 61
  - HeartMate, 57-58
  - LionHeart, 58-60
  - medications for, 61
  - methods of, 60
  - Novacor, 57-58
  - out-of-hospital program of, 60-61
  - patient selection for, 60
  - patient training for, 61
  - results of, 61-62
  - Thoratec IVAD System, 58

**Q****Q fever**

- in infective endocarditis diagnosis, 211-212

**Quality-of-life**

- exercise training effects on, 441-442

**R****Radiation dose**

- in CT, 518-519

**Radiation exposure**

- in coronary calcium scanning, 539

**Radiography**

- chest

- for pulmonary embolism, 629
- in infective endocarditis diagnosis, 192

**Reactive oxygen species**

- in vascular cells

- source of, 293-294

- in vascular diseases

- xanthine oxidase as source of, 295

**Rehabilitation**

- cardiac

- effects on cardiovascular outcomes.

- 435-448.** *See also Cardiac rehabilitation.*

**Renal diseases**

- chronic
  - dialysis and
  - management of, 385-386
- hyperlipidemia and
  - management of, 384-386
- in diabetics, 408

**Renal failure**

- in infective endocarditis, 165

**Right ventricular disease**

- quantitative CT methods in, 571-574

**Right-sided circulatory failure**

- mechanical circulatory support and, 32

**Right-sided native valve endocarditis**

- treatment of, 227

**Rotary pumps**

- as destination therapy, 69-70

**S****Scintigraphy**

- ventilation/perfusion lung
  - for pulmonary embolism, 629

**Sepsis**

- in infective endocarditis, 161-162

**Septic pulmonary emboli**

- in infective endocarditis, 164

**Shock**

- cardiogenic

- acute

- management of, **43-50.** *See also*

- Cardiogenic shock, acute, management of.*

- postcardiotomy

- short-term VADs for, 78-79

- postcardiotomy, 45-46

- precardiotomy, 46-48

**Shunt(s)**

- intracardiac, 31

- valve prosthesis/intracardiac

- long-term, 53

**Smoking**

- cigarette

- cessation of

- in cardiovascular disease prevention,

- 471-472

**Solid organ transplantation**

- hyperlipidemia after

- management of, 386-387

- Staphylococcus aureus* bacteremia, **219-233**

- cardiac valvular disease and, 221

community-acquired versus healthcare-associated, 221

comorbid conditions, 221-222

complicated versus uncomplicated treatment of, 224

complications of, 220-223

diagnosis of, 223-225

echocardiography of, 223-225

epidemiology of, 219-220

future directions in, 228-229

in surgical patients, 222

infectious endocarditis and, 222-223

identification of, 223

valve replacement therapy for, 228

metastatic

  risk factors for, 221-223

methicillin resistance in

  clinical impact of, 222

outcome of

  factors influencing, 222

prevalence of

  increasing, 219-220

prosthetic implants and, 221

treatment of, 225-228

*Staphylococcus aureus* endocarditis, 219-233

  antibiotic resistance to

   rates of, 220

  prevalence of, 220

Statin(s)

  for LDL-C in diabetes, 403-404

  for lipid disorders, 368

Stenosis(es)

  coronary artery

  epicardial

   microvascular dysfunction in presence of, 591-592

  severity of

  plaque rupture due to, 303-304

Step I and II diets

  in obesity management, 415-416

Strength

  exercise training and, 439

Stroke

  infective endocarditis and, 275-277

Sulfonylureas

  for hyperglycemia

  cardiovascular effects of, 402

Support persons

  in outpatient management of patients on long-term assist devices, 99-100

---

**T**

TAHs. *See Total artificial hearts (TAHs).*

Tandem Heart pVAD, 35-36

T-cell activation

  aberrant

    LVAD surface result in monocyte-T-cell interactions on, 129

T-cell defects

  in LVAD recipients, 132-134

Teeth

  infective endocarditis effects on, 149

Therapeutic lifestyle change

  in obesity management, 416

Thiazolidinediones

  for hyperglycemia

    cardiovascular effects of, 402

Thoratec IVAD System, 58

Thoratec Ventricular Assist System, 36-38

Thromboembolism

  mechanical circulatory support and, 32

Thrombosis(es)

  deep venous

    diagnostic tests for, 630-633. *See also Deep venous thrombosis, diagnostic tests for.*

  determinants of, 303-304

  in acute coronary syndromes, 303

  plaque composition and, 304-305

Total artificial hearts (TAHs), 105-117

  as destination therapy, 70

  CardioWest

  history of, 106-107

  evolution of, 6-10

  historical perspective of, 1-13

  implantation of, 110

    anticoagulation therapy and monitoring during, 110-113

    complications of, 113-115

    guidelines for, 110

    indications for, 110

    survival following, 113-115

    techniques for, 110

Trans fatty acids

  in obesity management, 419-421

Transesophageal echocardiography

  for pulmonary embolism, 630

Transplantation

  solid organ

Transplantation (*continued*)  
  hyperlipidemia after  
  management of, 386-387

Transportation issues  
  in outpatient management of patients on  
  long-term assist devices, 100

Trauma  
  aortic  
    MDCT of, 619-621

Travel issues  
  in outpatient management of patients on  
  long-term assist devices, 100

Triglyceride levels  
  dietary modification and, 422

**U**

Ultrasonography  
  intracoronary  
    in coronary arteriosclerosis and coronary  
    artery calcium, 524-527  
  venous  
    for deep venous thrombosis, 630

**V**

VADs. *See Ventricular assist devices (VADs)*.

Valve prosthesis/intracardiac shunts  
  long-term, 53

Valvular heart disease  
  extracorporeal mechanical circulatory support  
    devices for, 30-31  
  quantitative CT methods in, 575-579

Vancomycin  
  for infective endocarditis  
    complications of, 280-281

Vascular cells  
  reactive oxygen species in  
    source of, 293-294

Vascular diseases  
  nitric oxide bioavailability in, 292-293  
  reactive oxygen species in  
    xanthine oxidase as source of, 295

Vascular tone  
  endothelium as modulator of, 289-290  
  nitric oxide in regulation of, 290-291

Vasodilation  
  nitric oxide and, 291

Vasomotion  
  endothelial control of, 298-302

Vegetation(s)  
  surgical treatment for infective endocarditis  
    for, 245-246

Venography  
  contrast  
    for deep venous thrombosis, 630

Venous thromboembolic disease  
  CT in, 629-636. *See also Deep venous thrombosis, diagnostic tests for; Pulmonary embolism.*

Venous ultrasonography  
  for deep venous thrombosis, 630

Ventilation/perfusion lung scintigraphy  
  for pulmonary embolism, 629

Ventricular assist devices (VADs), 75-85  
  classification of, 24-25  
  for acute cardiogenic shock, 44-45  
  hemodynamic basis of, 24-25  
  hemodynamic characteristics of  
    fluid dynamic-rotary pumps, 24  
    hemodynamics characteristics of  
      axial flow pumps, 24-25  
      centrifugal pumps, 25  
      displacement pumps, 25  
  historical perspective of, 1-13  
  immunobiologic consequences of, 127-141  
  long-term, 52-55  
    blood types and, 54  
    diagnosis for, 54  
    early management with, 80  
    for right-sided circulatory failure, 53-54  
    future directions in, 55  
    indications for, 52  
    institutional criteria for, 52-53  
    myocardial recovery after, 79-84  
    patient selection for, 54, 80  
    preformed antibodies and, 54  
    results with, 82-83  
    size of, 54  
    support for, 54-55  
  valve prosthesis/intracardiac shunts, 53  
  ventricular recovery assessment with,  
    80-81  
    weaning patient from, 81

physiologic basis of, 15-24, 26  
ideal, 25-26  
interaction with native heart, 19-24  
  aortic valve-VAD interaction, 21  
  LVAD synchronization, 19-21

mitral valve-VAD interaction, 21-23  
right heart-LVAD interaction, 23-24  
tricuspid valve-VAD interaction, 23  
of heart failure, 17-18  
of recovery, 18-19  
ventricular physiology, 15-17  
practitioner's role in, 97-98  
pulsatile left  
development of, 2-6  
removal of  
described, 81-82  
rationale for, 75-76  
response to arrhythmias, 24  
response to congenital heart defects, 24  
response to coronary artery disease, 24  
short-term  
devices in, 78  
early management with, 77-78  
for acute fulminant myocarditis, 79  
for myocardial infarction, 79  
for postcardiotomy cardiogenic shock,  
78-79  
insertion of, 76-77  
myocardial recovery after  
demonstration of, 77-78  
patient selection for, 76  
selection of, 76-77  
unanswered questions related to, 83-84

#### Ventricular remodeling

heart failure progression and, 87-89. *See also*  
*Heart failure, progression of, left ventricular  
remodeling and.*

#### W

Warthin-Starry technique  
in infective endocarditis diagnosis, 208

Weight  
excess  
hypertriglyceridemia effects of, 422-423

Weight reduction  
in cardiovascular disease prevention, 475  
in hypertriglyceridemia management,  
422-423

Wine  
biology of, 452-453  
in vascular biology, 453-454  
moderate consumption of  
in cardiovascular disease prevention,  
**449-457**

#### Work issues

in outpatient management of patients on  
long-term assist devices, 101-102

#### Wound(s)

management of  
in outpatient management of patients on  
long-term assist devices, 99

#### X

Xanthine oxidase  
as source of reactive oxygen species in vascular  
diseases, 295



